Sorry, I missed your message. Regarding Epifix vs Grafix, anecdotally speaking, the consensus appears to be that they are comparable for DFUs. As you know, there isn't any head to head data to claim that one is superior. I do not know if there is any clinical significance to using MSCs on diabetic ulcers. For other indications, perhaps.
Here is what I believe that physicians are prioritizing:
1) Is it covered my managed care?
2) Ease of use, time spent applying
IMO, Epifix has the advantage for 1 and 2. They are leaps ahead of Osiris with CMS and the VA System. You can also make an argument that MDXG is ahead in terms of being first to market which which is also an advantage by shaping physician perceptions before the competition.
As effective as these products are, I believe that additional entrants will allow the government to implement more pricing controls via competitive bidding. I like MDXG's prospects when you add in Epifix. MDXG has distribution agreements with Medtronic and Zimmer. That speaks volumes as those are two of the biggest players in Ortho / Spine. I do not know of any major agreements with Orirus.
Currently, there is rather significant short interest in MDXG and it's keeping the SP from advancing. MDXG revenues will trigger the shorts to cover.
Recent MDXG News
- MIMEDX Announces First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/30/2024 08:01:00 PM
- MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- MIMEDX Introduces E-Commerce and Account Management Platform • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:28:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:27:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:11:28 PM
- MIMEDX Announces Appointment of Two New Independent Directors • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:22:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:02:35 PM
- MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 02/28/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:40:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:55:24 PM
- MIMEDX to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 09:22:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 08:11:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 09:13:13 PM
- MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28 • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:09:53 PM
- MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing • GlobeNewswire Inc. • 01/22/2024 01:00:00 PM
- MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook • GlobeNewswire Inc. • 12/29/2023 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM